公开(公告)号：US20250002994A1

公开(公告)日：2025-01-02

申请号：US18882446

申请日：2024-09-11

Applicant: Illumina Cambridge Limited

Inventor： Nikolai Nikolaevich Romanov ,  Patrick McCauley ,  Niall Hynes

IPC: C12Q1/6869 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04 ,  C07H19/06 ,  C07H19/16

Abstract: The present application relates to tertiary amine substituted coumarin derivatives and their uses as fluorescent labels. These compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.

公开(公告)号：US20240150827A1

公开(公告)日：2024-05-09

申请号：US18488801

申请日：2023-10-17

Applicant: Illumina Cambridge Limited

Inventor： Antoine FRANCAIS ,  Elena CRESSINA ,  Adam CULLEY ,  Angelica MARIANI ,  Xiaolin WU ,  Xiaohai LIU

IPC: C12Q1/6869 ,  C07H19/06 ,  C07H19/16 ,  C07H21/00

CPC classification number: C12Q1/6869 ,  C07H19/06 ,  C07H19/16 ,  C07H21/00

Abstract: Embodiments of the present disclosure relate to nucleotide molecules with a 3′ AOM blocking group. Also provided herein are methods to prepare such nucleotide molecules, and the uses of fully functionalized nucleotides containing the 3′-OH blocking group for sequencing applications.

公开(公告)号：US11970735B2

公开(公告)日：2024-04-30

申请号：US17417332

申请日：2020-01-07

Applicant: Singular Genomics Systems, Inc.

Inventor： Ronald Graham ,  Olga Adelfinskaya ,  Megha Cila ,  Rodrigo Rodriguez

IPC: C12Q1/6869 ,  C07F9/655 ,  C07H19/06 ,  C07H19/10 ,  C07H19/14 ,  C07H19/16 ,  C07H19/20 ,  C12N9/12 ,  C12Q1/6806

CPC classification number: C12Q1/6869 ,  C07F9/65515 ,  C07H19/06 ,  C07H19/10 ,  C07H19/14 ,  C07H19/16 ,  C07H19/20 ,  C12N9/1241 ,  C12Q1/6806 ,  C12Q2334/40 ,  C12Q2521/101 ,  C12Q2525/101 ,  C12Q2535/00

Abstract: Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof for sequencing a nucleic acid.

公开(公告)号：US20240116973A1

公开(公告)日：2024-04-11

申请号：US18272448

申请日：2022-01-14

Applicant: ALNYLAM PHARMACEUTICALS, INC.

Inventor： Muthiah MANOHARAN ,  Dhrubajyoti DATTA

IPC: C07H19/16 ,  C12N15/113

CPC classification number: C07H19/16 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/333 ,  C12N2310/344

Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) molecules comprising a 6-methyladenine nucleobase and capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.

公开(公告)号：US20240010669A1

公开(公告)日：2024-01-11

申请号：US18227782

申请日：2023-07-28

Applicant: Academia Sinica

Inventor： Chih-Cheng CHEN ,  Jim-Min FANG ,  Cheng-Han LEE ,  Jen-Yao CHANG

IPC: C07H19/16 ,  A61K47/55 ,  A61P29/00 ,  A61K31/7076 ,  A61K38/04

CPC classification number: C07H19/16 ,  A61K47/55 ,  A61P29/00 ,  A61K31/7076 ,  A61K38/046

Abstract: Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N6-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, the compound is 5′-glycylcarbonyl-N6-(4-hydroxybenzyl)adenosine (I-a1). In another embodiment of the invention, the compound is 5′-deoxy-5′-(N′-glycylureido)-N6-(4-hydroxybenzyl)adenosine (I-d1). Also disclosed are methods of making and using the same.

公开(公告)号：US20230374058A1

公开(公告)日：2023-11-23

申请号：US18359297

申请日：2023-07-26

Applicant: ROME Therapeutics, Inc.

Inventor： Donna L. ROMERO ,  Oliver Saunders ,  Gregory Stuart Bisacchi ,  Dennis Zaller ,  Rosana Kapeller-Libermann

IPC: C07H19/10 ,  C07H19/06 ,  C07H19/16 ,  C07H19/12 ,  A61P37/06

CPC classification number: C07H19/10 ,  C07H19/06 ,  C07H19/16 ,  C07H19/12 ,  A61P37/06

Abstract: The invention provides compounds, compositions and methods for treating medical disorders, such as cancer, an autoimmune disorder, and/or a neurological disorder, and inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase using a compound according to Formula I or a pharmaceutically acceptable salt thereof, or a related compound provided herein.

公开(公告)号：US20230365614A1

公开(公告)日：2023-11-16

申请号：US18125072

申请日：2023-03-22

Applicant: Pacific Biosciencesof California, Inc.

Inventor： Keith Bjornson ,  Jeremiah Hanes ,  Erik Miller ,  Satwik Kamtekar ,  Lubomir Sebo ,  Louis Brogley

IPC: C07H21/04 ,  C07K14/36 ,  C07H19/06 ,  G01N33/58 ,  C12Q1/6874 ,  C12Q1/6869 ,  C07H19/16 ,  C12N9/10 ,  C09B23/08 ,  C09B69/10

CPC classification number: C07H21/04 ,  C07K14/36 ,  C07H19/06 ,  G01N33/583 ,  C12Q1/6874 ,  C12Q1/6869 ,  C07H19/16 ,  G01N33/582 ,  C12N9/10 ,  C09B23/083 ,  C09B69/105 ,  C12Q2535/113 ,  C12Q2523/313 ,  C12Q2563/131 ,  C12Q2563/107

Abstract: Compositions, methods, and systems are provided for fluorescent polymerase enzyme substrates comprising protein shields for improving enzyme photostability in single molecule real time sequencing. Fluorescent polymerase enzyme substrates of the invention have a protein shield between the fluorescent dye moieties and nucleotide moieties of the polymerase enzyme substrate. The polymerase enzyme substrates have a nucleotide component and a dye component, each attached to a protein. The attachments can be covalent. The protein can, for example, prevent the direct interaction of the fluorescent dye moiety with the enzyme when carrying out nucleotide synthesis, preventing photodamage to the enzyme. The polymerase enzyme substrates of the invention can have multiple dyes and multiple nucleotide moieties.

公开(公告)号：US20230348968A1

公开(公告)日：2023-11-02

申请号：US18313227

申请日：2023-05-05

Applicant: Illumina Cambridge Limited

Inventor： Elena Cressina ,  Antoine Francais ,  Xiaohai Liu

IPC: C12Q1/6869 ,  C07H19/06 ,  C07H21/00 ,  C07H19/16 ,  C07H19/20 ,  C07H19/10 ,  C07H19/073 ,  C07H19/14 ,  C07H21/04 ,  C12Q1/6809 ,  C12Q1/6816

CPC classification number: C12Q1/6869 ,  C07H19/06 ,  C07H21/00 ,  C07H19/16 ,  C07H19/20 ,  C07H19/10 ,  C07H19/073 ,  C07H19/14 ,  C07H21/04 ,  C12Q1/6809 ,  C12Q1/6816

Abstract: The present disclosure relates to new nucleotide and oligonucleotide compounds and their use in nucleic acid sequencing applications.

公开(公告)号：US20230295213A1

公开(公告)日：2023-09-21

申请号：US17993937

申请日：2022-11-24

Applicant: RISEN (SUZHOU) PHARMA TECH CO., LTD.

Inventor： Jiasheng LU ,  Gang CHEN ,  Qiguo ZHANG ,  Xianqi KONG ,  Dawei CHEN ,  Chuanhao HUANG ,  Xingwu ZHU ,  Yuhua ZHANG

IPC: C07H19/20 ,  C07H19/16 ,  C07F9/6561

CPC classification number: C07H19/20 ,  C07H19/16 ,  C07F9/65616

Abstract: CD73 (also known as ecto-5′-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I′ and pharmaceutically acceptable esters or salts thereof.

公开(公告)号：US11753433B2

公开(公告)日：2023-09-12

申请号：US17222515

申请日：2021-04-05

Applicant: Epizyme, Inc.

Inventor： Edward James Olhava

IPC: A01N43/04 ,  A61K31/70 ,  C07H19/16 ,  A61K31/7076 ,  A61K31/4184 ,  C07D235/12 ,  C07H19/06 ,  C07H19/067 ,  C07H1/06 ,  C07H19/167

CPC classification number: C07H19/16 ,  A61K31/4184 ,  A61K31/7076 ,  C07D235/12 ,  C07B2200/13 ,  C07H1/06 ,  C07H19/06 ,  C07H19/067 ,  C07H19/167 ,  Y02A50/30

Abstract: The present invention provides an efficient process for the synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also provides novel crystalline forms of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof (Form A, Form B, and Form C), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure.